-DOCSTART- -X- O
The -X- _ O
anticancer -X- _ O
potential -X- _ O
of -X- _ O
catechins -X- _ B-Intervention
derived -X- _ O
from -X- _ O
green -X- _ O
tea -X- _ O
is -X- _ O
not -X- _ O
well -X- _ O
understood -X- _ O
, -X- _ O
in -X- _ O
part -X- _ O
because -X- _ O
catechin-related -X- _ O
growth -X- _ O
suppression -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
apoptosis -X- _ O
appears -X- _ O
to -X- _ O
vary -X- _ O
with -X- _ O
the -X- _ O
type -X- _ O
and -X- _ O
stage -X- _ O
of -X- _ O
malignancy -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
with -X- _ O
the -X- _ O
type -X- _ B-Intervention
of -X- _ I-Intervention
catechin. -X- _ I-Intervention
This -X- _ O
in -X- _ O
vitro -X- _ O
study -X- _ O
examined -X- _ O
the -X- _ O
biological -X- _ O
effects -X- _ O
of -X- _ O
epicatechin -X- _ B-Intervention
( -X- _ I-Intervention
EC -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
epigallocatechin -X- _ I-Intervention
( -X- _ I-Intervention
EGC -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
EC -X- _ I-Intervention
3-gallate -X- _ I-Intervention
( -X- _ I-Intervention
ECG -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
EGC -X- _ I-Intervention
3-gallate -X- _ I-Intervention
( -X- _ I-Intervention
EGCG -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
cell -X- _ O
lines -X- _ O
from -X- _ O
human -X- _ B-Patient
gender-specific -X- _ I-Patient
cancers. -X- _ I-Patient
Cell -X- _ O
lines -X- _ O
developed -X- _ O
from -X- _ O
organ-confined -X- _ O
( -X- _ O
HH870 -X- _ O
) -X- _ O
and -X- _ O
metastatic -X- _ O
( -X- _ O
DU145 -X- _ O
) -X- _ O
prostate -X- _ O
cancer -X- _ O
, -X- _ O
and -X- _ O
from -X- _ O
moderately -X- _ O
( -X- _ O
HH450 -X- _ O
) -X- _ O
and -X- _ O
poorly -X- _ O
differentiated -X- _ O
( -X- _ O
HH639 -X- _ O
) -X- _ O
epithelial -X- _ O
ovarian -X- _ O
cancer -X- _ O
were -X- _ O
grown -X- _ O
with -X- _ O
or -X- _ O
without -X- _ B-Comparision
EC -X- _ I-Comparision
, -X- _ I-Comparision
EGC -X- _ I-Comparision
, -X- _ I-Comparision
ECG -X- _ I-Comparision
or -X- _ I-Comparision
EGCG. -X- _ I-Comparision
When -X- _ O
untreated -X- _ O
cells -X- _ O
reached -X- _ O
confluency -X- _ O
, -X- _ O
viability -X- _ O
and -X- _ O
doubling -X- _ O
time -X- _ O
were -X- _ O
measured -X- _ O
for -X- _ O
treated -X- _ B-Intervention
and -X- _ O
untreated -X- _ B-Comparision
cells. -X- _ I-Comparision
Whereas -X- _ O
EC -X- _ B-Intervention
treatment -X- _ I-Intervention
reduced -X- _ B-Outcome
proliferation -X- _ I-Outcome
of -X- _ I-Outcome
HH639 -X- _ I-Outcome
cells -X- _ I-Outcome
by -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ O
EGCG -X- _ B-Intervention
suppressed -X- _ B-Outcome
proliferation -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
cell -X- _ I-Outcome
lines -X- _ I-Outcome
by -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ O
ECG -X- _ B-Intervention
was -X- _ B-Outcome
even -X- _ I-Outcome
more -X- _ I-Outcome
potent -X- _ I-Outcome
: -X- _ O
it -X- _ O
inhibited -X- _ O
DU145 -X- _ O
, -X- _ O
HH870 -X- _ O
, -X- _ O
HH450 -X- _ O
and -X- _ O
HH639 -X- _ O
cells -X- _ O
at -X- _ O
concentrations -X- _ O
of -X- _ O
24 -X- _ O
, -X- _ O
27 -X- _ O
, -X- _ O
29 -X- _ O
and -X- _ O
30 -X- _ O
μM -X- _ O
, -X- _ O
whereas -X- _ O
EGCG -X- _ O
inhibited -X- _ O
DU145 -X- _ O
, -X- _ O
HH870 -X- _ O
, -X- _ O
HH450 -X- _ O
and -X- _ O
HH639 -X- _ O
cells -X- _ O
at -X- _ O
concentrations -X- _ O
89 -X- _ O
, -X- _ O
45 -X- _ O
, -X- _ O
62 -X- _ O
and -X- _ O
42 -X- _ O
μM. -X- _ O
When -X- _ O
compared -X- _ O
with -X- _ O
EGCG -X- _ B-Intervention
, -X- _ I-Intervention
ECG -X- _ I-Intervention
more -X- _ B-Outcome
effectively -X- _ I-Outcome
suppresses -X- _ I-Outcome
the -X- _ I-Outcome
growth -X- _ I-Outcome
of -X- _ I-Outcome
prostate -X- _ I-Outcome
cancer -X- _ I-Outcome
and -X- _ I-Outcome

epithelial -X- _ B-Outcome
ovarian -X- _ I-Outcome
cancer -X- _ I-Outcome
cell -X- _ O
lines -X- _ O
derived -X- _ O
from -X- _ O
tumors -X- _ O
of -X- _ O
patients -X- _ O
with -X- _ O
different -X- _ O
stages -X- _ O
of -X- _ O
disease -X- _ O
. -X- _ O

